ArticleScience (New York, N.Y.)2021
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 1 synthesis or guideline pooled it, 248 citations in OpenAlex.
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.Developmental cell · 2026Article
- An immune-poised state of human bronchial epithelial cells mediates defense against RSV in adults.Nature communications · 2026Article
- Omics-based decoding of molecular and metabolic crosstalk in the skin barrier ecosystem.Cell death and differentiation · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer.Cancer research · 2026Article
- Fibroblasts as regulators of lung immunity, repair and fibrosis.Nature reviews. Immunology · 2026Review
- GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma.Cell reports · 2026Article
- High-quality acinar cell isolation enables single-cell analysis of healthy and injured pancreas.Cell reports methods · 2026Article
- Pancreatic cancer.Nature reviews. Disease primers · 2026Review
- DNA hypermethylation of nonspecific cytotoxic cell receptor protein 1 and poor prognosis of pancreatic cancer.Oncology letters · 2026Article
- Beyond re-epithelialization: prolonged remodeling re-establishes epithelial homeostasis in oral mucosa.Cell death & disease · 2026Article
- Remembrance of inflammations past.Nature · 2026Article
- Epigenetic memory of colitis promotes tumour growth.Nature · 2026Article
- Distinctive DNA sequence features define epigenetic longevity of inflammatory memory.Science (New York, N.Y.) · 2026Article
- GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma.Cancer research · 2026Article
- Article
- Association of Autoimmune Diseases With Pancreatic Cancer: A Nationwide Follow-Up Study From Sweden.Cancer medicine · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byUnder pressure.2021
Authors and funding
33 authors at 6 institutions in 3 countries.
Edoardo Del Poggetto *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3648-4399
I-Lin Ho *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8914-710X
Chiara BalestrieriExperimental Hematology Unit, San Raffaele Research Hospital, Milan 20132, Italy.ORCID 0000-0001-7362-3530
Er-Yen YenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2918-5419
Shaojun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5760-5797
Francesca CitronDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5896-3008
Rutvi ShahDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2382-9175
Denise CortiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9841-8143
Giuseppe R DiaferiaDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan 20139, Italy.ORCID 0000-0003-4022-8483
Chieh-Yuan LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-1038-5218
Sara LoponteDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2849-5805
Federica CarboneDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8697-0304
Yoku HayakawaDepartment of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-3988-2499
Giovanni ValentiDepartment of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, USA.
Shan JiangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Luigi SapioDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hong JiangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Prasenjit DeyDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6678-503X
Sisi GaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4809-1699
Angela K DeemDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Stefan Rose-JohnDepartment of Biochemistry, Christian-Albrechts-Universität zu Kiel, Kiel 24098, Germany.ORCID 0000-0002-7519-3279
Wantong YaoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0172-7530
Haoqiang YingDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0616-2310
Andrew D RhimDepartment of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Giannicola GenoveseDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Timothy P HeffernanTRACTION, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3166-8922
Anirban MaitraSheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7923-9978
Timothy C WangDepartment of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-2095-0121
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-9380-0266
Giulio F DraettaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5225-9610
Alessandro CarugoTRACTION, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5182-3320
Gioacchino NatoliDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan 20139, Italy.
Andrea VialeDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4328-1044
The University of Texas MD Anderson Cancer Center · USColumbia University Irving Medical Center · USChristian-Albrechts-Universität zu Kiel · DEEuropean Institute of Oncology · ITHumanitas University · ITVita-Salute San Raffaele University · IT
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MProject 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0MMitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancerR01CA258917 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VIALE, ANDREA · 2021 to 2025
$2.3MRole of type 2 immune response in pancreatic cancer tumorigenesisR01CA262822 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DEY, PRASENJIT · 2021 to 2025
$2.2MTargeting Malic Enzyme 3 as a Synthetic Lethality Target in Pancreatic CancerR00CA218891 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DEY, PRASENJIT · 2019 to 2021
$747kTargeting malic enzyme 3 as a synthetic lethality target in pancreatic cancerK99CA218891 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEY, PRASENJIT · 2018 to 2019
$171kNCI NIH HHS K99 CA218891NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221707NCI NIH HHS R00 CA218891NCI NIH HHS R01 CA258917NCI NIH HHS R01 CA262822
Abstract
Inflammation is a major risk factor for pancreatic ductal adenocarcinoma (PDAC). When occurring in the context of pancreatitis, KRAS mutations accelerate tumor development in mouse models. We report that long after its complete resolution, a transient inflammatory event primes pancreatic epithelial cells to subsequent transformation by oncogenic KRAS. Upon recovery from acute inflammation, pancreatic epithelial cells display an enduring adaptive response associated with sustained transcriptional and epigenetic reprogramming. Such adaptation enables the reactivation of acinar-to-ductal metaplasia (ADM) upon subsequent inflammatory events, thereby limiting tissue damage through a rapid decrease of zymogen production. We propose that because activating mutations of KRAS maintain an irreversible ADM, they may be beneficial and under strong positive selection in the context of recurrent pancreatitis.
Indexed as
CarcinogenesisGenes, rasAcinar CellsAnimalsCarcinoma, Pancreatic DuctalCells, CulturedCell Transformation, NeoplasticCellular ReprogrammingChromatinEarly Growth Response Protein 1Enzyme PrecursorsEpigenesis, GeneticEpithelial CellsFemaleMaleMAP Kinase Signaling SystemChromatinEarly Growth Response Protein 1Egr1 protein, mouseEnzyme Precursors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.